FY2026 Earnings Estimate for BEAM Issued By HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Beam Therapeutics in a report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($3.30) for the year. HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics' FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($1.91) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.01). The firm had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's revenue for the quarter was down 16.9% compared to the same quarter last year. During the same period last year, the business earned ($1.22) earnings per share.

A number of other research firms also recently weighed in on BEAM. Royal Bank of Canada decreased their price objective on Beam Therapeutics from $27.00 to $24.00 and set a "sector perform" rating on the stock in a report on Wednesday, November 6th. Cantor Fitzgerald upgraded Beam Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Wednesday, January 29th. Scotiabank started coverage on Beam Therapeutics in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $24.00 price objective for the company. Leerink Partners raised shares of Beam Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein raised Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Beam Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $47.67.

Beam Therapeutics Stock Performance

Shares of NASDAQ:BEAM traded down $0.24 during midday trading on Wednesday, reaching $27.41. 1,129,389 shares of the company's stock were exchanged, compared to its average volume of 1,048,712. The firm has a market capitalization of $2.27 billion, a PE ratio of -15.57 and a beta of 1.92. The company's 50 day simple moving average is $26.50 and its two-hundred day simple moving average is $25.79. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $49.50.

Insider Activity

In related news, CEO John M. Evans sold 30,000 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now directly owns 908,659 shares of the company's stock, valued at approximately $24,306,628.25. The trade was a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Beam Therapeutics

Several hedge funds have recently made changes to their positions in BEAM. Sumitomo Mitsui Trust Group Inc. lifted its position in Beam Therapeutics by 59.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company's stock worth $87,044,000 after buying an additional 1,328,414 shares in the last quarter. ARK Investment Management LLC increased its position in shares of Beam Therapeutics by 8.2% during the 4th quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company's stock worth $175,287,000 after purchasing an additional 536,930 shares during the last quarter. State Street Corp raised its stake in shares of Beam Therapeutics by 12.5% during the 3rd quarter. State Street Corp now owns 3,929,557 shares of the company's stock worth $96,274,000 after purchasing an additional 437,402 shares in the last quarter. Peregrine Investment Management Inc. acquired a new stake in shares of Beam Therapeutics in the 4th quarter valued at approximately $3,932,000. Finally, Bellevue Group AG grew its stake in shares of Beam Therapeutics by 7.1% in the third quarter. Bellevue Group AG now owns 1,518,121 shares of the company's stock valued at $37,194,000 after buying an additional 100,000 shares in the last quarter. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.